Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere
Selv om mange ulike medikamentgrupper er ototoksiske (cytostatika, aminoglykosider, loopdiuretika og NSAIDS), vil det i praksis kun være aktuelt å monitorere ototoksisitet i forbindelse med aminoglykosider.
Ved mistanke om hørselstap ved bruk av ototoksiske medikamenter, er behandlende pediater ansvarlig for å henvise barnet til audiologisk oppfølging. Øre-nese-halslege er deretter ansvarlig for videre utredning.
Aminoglykosider er en gruppe antibiotika som bl.a. benyttes i behandlingen av infeksjoner hos nyfødte. Risikoen for hørselstap ved aminoglykosider og evt. samtidig furosemid er lav ved behandling innenfor terapeutisk serumnivå.
76. Vos, B, Senterre, C, Lagasse, R, Leveque, A. Newborn hearing screening programme in Belgium: a consensus recommendation on risk factors. BMC Pediatrics. 2015. 15. 1. 160.
8. Thompson, DC, McPhillips, H, Davis, RL, Lieu, TL, Homer, CJ, Helfand, M. Universal newborn hearing screening: summary of evidence. The Journal of the American Medical Association. 2001. 286. 16. 2000-2010.
79. NSHP Clinical Group. Sutton, G (ed). Guidelines for surveillanceand audiological referral of infants and children following the newborn hearing screen. 2012. versions 5.1.
29. Nelson, HD, Bougatsos, C, Nygren, P. Universal Newborn Hearing Screening: Systematic Review to Update the 2001 US Preventive Services Task Force Recommendations. The Journal of Pediatrics. 2008. 122. 1. e266-e276.
101. Bindu, LH et al. Genetics of aminoglucoside-induced and prelingual non-syndromic mitochondrial hearing impairment: a review. International Journal of Audiology. 2008. 47. 199-208.
102. Brock, PR et al. Patinum-induced ototoxicity in children: A consensus review on mecanisms, predisposition and protection, including a new international society of pediatric oncology Boston ototoxicity scale. Journal of Clinical Oncology. 2012. 30. 19. 2408-2417.
103. Huizing, EH, de Groot, JC. Human cochlear pathology in aminoglycoside ototoxicity. Acta Otolaryngology. 1987. Suppl. 436. 117-125.
104. Campbell, KC, Durrant, J. Audiologic monitoring for ototoxicity. Otolaryngologic Clinics of North America. 1993. 47. 11. 903-914.
105. Fjalstad, JW, Laukli, E, van den Anker, JN, Klingenberg, C. High-dose gentamicin in newborn infants: is it safe?. European Journal of Pediatrics. 2014. 173. 4. 489-495.
106. Setiabudy, R, Suwento, R, Rundjan, L, Yasin, FH, Louisa, M, Dwijayanti, A et al. Lack of a relationship between the serum concentration of aminoglycosides and ototoxity in neonates. International Journal of Clinical Pharmacy and Therapeutics. 2013. 51. 5. 401-406.
107. de Hoog, M, van Zanten, BA, Hop, WC, Overbosch, E, Weisglas-Kuperus, N, Van den Anker, JN. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. The Journal of Pediatrics. 2003. 142. 1. 41-46.
108. Johnson, RF, Cohen, AP, Guo, Y, Schibler, K, Greinwald, JH. Genetic mutations and aminoclycoside-induced ototoxity in neonates. Otoralyngology - Head and Neck Surgery. 2010. 142. 5. 704-707.
109. Estivill, X, Govea, N, Barcelo, E, Badenas, C, Romero, E, Moral, L et al. Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. American Journal of Human Genetics. 1998. 62. 1. 27-35.
110. Robertson, CM, Tyebkhan, JM, Peliowski, A, Etches, PC, Cheung, PY. Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure. Acta Paediatrica. 2006. 95. 2. 214-223.
111. Brown, DR, Watchko, JF, Sabo, D. Neonatal sensorineural hearing loss associated with furosemide: a case-control study. Developmental Medicine and Child Neurology. 1991. 33. 9. 816-823.
Siste faglige endring: 23. januar 2017 Se tidligere versjoner
Helsedirektoratet (2016). Når nyfødte får ototoksiske medikamenter, bør man i utvalgte tilfeller henvise til audiologisk oppfølging. [nettdokument]. Oslo: Helsedirektoratet (siste faglige endring 23. januar 2017, lest 25. desember 2024). Tilgjengelig fra https://www.helsedirektoratet.no/retningslinjer/screening-av-horsel-hos-nyfodte/nyfodte-med-behov-for-audiologisk-utredning-og-oppfolging/nar-nyfodte-far-ototoksiske-medikamenter-bor-man-i-utvalgte-tilfeller-henvise-til-audiologisk-oppfolging